{"id":"dutasteride-capsules","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Erectile dysfunction"},{"rate":"2-4","effect":"Decreased libido"},{"rate":"1-3","effect":"Ejaculation disorder"},{"rate":"0.4-1","effect":"Gynecomastia"},{"rate":"0.5-1","effect":"Breast tenderness"}]},"_chembl":null,"_dailymed":{"setId":"0a334eb9-cacf-f213-e063-6394a90a46da","title":"DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE (DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CAPSULES) CAPSULE [AVKARE]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting 5-alpha reductase, dutasteride prevents the formation of DHT, the primary androgen responsible for prostate growth. This leads to shrinkage of an enlarged prostate and reduction in urinary symptoms associated with benign prostatic hyperplasia. The dual inhibition of both enzyme isoforms makes it more potent than selective type 1 inhibitors.","oneSentence":"Dutasteride inhibits both type 1 and type 2 5-alpha reductase enzymes, blocking the conversion of testosterone to dihydrotestosterone (DHT) and reducing DHT levels in the prostate.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:25.984Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms"}]},"trialDetails":[{"nctId":"NCT07444385","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects","status":"RECRUITING","sponsor":"Addpharma Inc.","startDate":"2026-02-26","conditions":"Benign Prostatic Hyperplasia","enrollment":44},{"nctId":"NCT05513365","phase":"PHASE2","title":"Phase II Dutasteride in Combination With CAB vs CAB in SDC","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2022-09-27","conditions":"Salivary Duct Carcinoma","enrollment":26},{"nctId":"NCT04098302","phase":"PHASE2, PHASE3","title":"Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy","status":"COMPLETED","sponsor":"UConn Health","startDate":"2019-10-15","conditions":"Alcohol Use Disorder","enrollment":180},{"nctId":"NCT06916793","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2025-04-30","conditions":"Androgenetic Alopecia","enrollment":288},{"nctId":"NCT06677177","phase":"NA","title":"The Efficacy of Nano-water in Combination With Tamsulosin- Dutasteride for Lower Urinary Tract Symptoms","status":"COMPLETED","sponsor":"ALI KAMAL M. SAMI","startDate":"2016-02-16","conditions":"Lower Urinary Tract Symptoms","enrollment":210},{"nctId":"NCT04677855","phase":"PHASE1","title":"Study of PCUR-101 in Combination With ADT in Patients With mCRPC","status":"TERMINATED","sponsor":"Pellficure Pharmaceuticals, Inc","startDate":"2021-03-30","conditions":"Prostate Cancer","enrollment":7},{"nctId":"NCT06264414","phase":"PHASE3","title":"Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia","status":"NOT_YET_RECRUITING","sponsor":"EMS","startDate":"2025-02","conditions":"Prostatic Hyperplasia, Benign, Erectile Dysfunction","enrollment":262},{"nctId":"NCT06233227","phase":"PHASE1","title":"Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-09-24","conditions":"Healthy Subjects","enrollment":28},{"nctId":"NCT00668642","phase":"PHASE2","title":"Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Endeavor Health","startDate":"2007-03","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT02352311","phase":"PHASE1","title":"Safety and Pharmacokinetic Characteristics of DKF-313","status":"COMPLETED","sponsor":"Dongkook Pharmaceutical Co., Ltd.","startDate":"2015-01","conditions":"Benign Prostate Hyperplasia, Healthy","enrollment":54},{"nctId":"NCT04214808","phase":"PHASE1","title":"To Evaluate the Pharmacokinetics and Safety of AD-208","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2020-01-03","conditions":"Androgenetic Alopecia","enrollment":24},{"nctId":"NCT00082043","phase":"PHASE1","title":"Dutasteride to Treat Women With Menstrually Related Mood Disorders","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2004-03-31","conditions":"Premenstrual Syndrome, PMS, Healthy","enrollment":34},{"nctId":"NCT02058368","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-10","conditions":"Prostatic Hyperplasia","enrollment":607},{"nctId":"NCT02014584","phase":"PHASE3","title":"Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2014-07-02","conditions":"Alopecia","enrollment":117},{"nctId":"NCT02058576","phase":"PHASE1","title":"Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in Fed State","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-11","conditions":"Urologic Diseases","enrollment":77},{"nctId":"NCT02052713","phase":"PHASE1","title":"Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted State","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-19","conditions":"Urologic Diseases","enrollment":78},{"nctId":"NCT01777269","phase":"PHASE4","title":"Prospective Sexual Function Study for BPH Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-18","conditions":"Prostatic Hyperplasia","enrollment":489},{"nctId":"NCT01294592","phase":"PHASE4","title":"Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-22","conditions":"Prostatic Hyperplasia","enrollment":742},{"nctId":"NCT01831791","phase":"PHASE3","title":"A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04-14","conditions":"Alopecia","enrollment":120},{"nctId":"NCT01577693","phase":"PHASE1","title":"Study to Compare the Bioavailability of Dutasteride Novel Formulation Form to the Soft Gel Capsule Form in Healthy Male Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-05-12","conditions":"Prostatic Hyperplasia","enrollment":35},{"nctId":"NCT02509104","phase":"PHASE1","title":"Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-30","conditions":"Prostatic Hyperplasia","enrollment":56},{"nctId":"NCT01471678","phase":"PHASE1","title":"Bioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) in Asian Males.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-06-30","conditions":"Prostatic Hyperplasia","enrollment":27},{"nctId":"NCT01495026","phase":"PHASE1","title":"A Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mg) in Healthy Male Subjects From North East Asia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-06","conditions":"Prostatic Hyperplasia","enrollment":63},{"nctId":"NCT02578953","phase":"PHASE1","title":"Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-09-09","conditions":"Prostatic Hyperplasia","enrollment":36},{"nctId":"NCT02184585","phase":"PHASE1","title":"Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-10","conditions":"Prostatic Hyperplasia","enrollment":84},{"nctId":"NCT01929330","phase":"PHASE1","title":"Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-09-23","conditions":"Alopecia","enrollment":36},{"nctId":"NCT03240939","phase":"PHASE1","title":"Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil","status":"COMPLETED","sponsor":"Yuyu Pharma, Inc.","startDate":"2017-03-27","conditions":"Benign Prostatic Hyperplasia","enrollment":36},{"nctId":"NCT00537654","phase":"PHASE1","title":"A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-18","conditions":"Prostatic Hyperplasia","enrollment":81},{"nctId":"NCT01657851","phase":"PHASE1","title":"Bioequivalence - Duodart Against Avodart & Omnic","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-08-23","conditions":"Prostatic Hyperplasia","enrollment":35},{"nctId":"NCT01254071","phase":"PHASE1","title":"A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-10","conditions":"Prostatic Hyperplasia","enrollment":86},{"nctId":"NCT01262287","phase":"PHASE4","title":"Dutasteride for the Reduction of Alcohol Use in Male Drinkers","status":"COMPLETED","sponsor":"UConn Health","startDate":"2011-01","conditions":"Alcoholism, Alcohol Abuse, Alcohol Dependence","enrollment":47},{"nctId":"NCT00553878","phase":"PHASE2, PHASE3","title":"Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"Canadian Urology Research Consortium","startDate":"2007-03","conditions":"Prostate Cancer","enrollment":100},{"nctId":"NCT01376284","phase":"","title":"Drug Use Investigation for AVOLVE(BPH)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12","conditions":"Prostatic Hyperplasia","enrollment":1000},{"nctId":"NCT00805701","phase":"PHASE4","title":"Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation","status":"COMPLETED","sponsor":"Bay State Clinical Trials, Inc.","startDate":"2009-01","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT00706966","phase":"NA","title":"MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2005-06","conditions":"Nonmalignant Neoplasm, Prostate Cancer","enrollment":10},{"nctId":"NCT00527605","phase":"PHASE3","title":"Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10","conditions":"Benign Prostatic Hyperplasia, Prostatic Hyperplasia","enrollment":253},{"nctId":"NCT00558363","phase":"PHASE2","title":"ARTS - AVODART After Radical Therapy For Prostate Cancer Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11","conditions":"Neoplasms, Prostate, Prostate Cancer After a Radical Treatment","enrollment":294},{"nctId":"NCT00690950","phase":"PHASE4","title":"A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart","status":"UNKNOWN","sponsor":"Urologic Consultants of Southeastern PA","startDate":"2008-05","conditions":"Benign Prostatic Hyperplasia","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"ASTHENIA"},{"count":4,"reaction":"DRUG INEFFECTIVE"},{"count":3,"reaction":"ASTHMA"},{"count":3,"reaction":"BLOOD COUNT ABNORMAL"},{"count":3,"reaction":"PLATELET COUNT DECREASED"},{"count":3,"reaction":"PNEUMONIA"},{"count":3,"reaction":"WHEEZING"},{"count":2,"reaction":"ANAEMIA"},{"count":2,"reaction":"ATRIAL FIBRILLATION"},{"count":2,"reaction":"BRAIN INJURY"}],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avodart"],"phase":"marketed","status":"active","brandName":"Dutasteride Capsules","genericName":"Dutasteride Capsules","companyName":"UConn Health","companyId":"uconn-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dutasteride inhibits both type 1 and type 2 5-alpha reductase enzymes, blocking the conversion of testosterone to dihydrotestosterone (DHT) and reducing DHT levels in the prostate. Used for Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}